【摘要】 目的:评价吉西他滨联合奥沙利铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副作用。方法:2005年1月~2008年1月住院的NSCLC患者48例,其中鳞癌23例、腺癌16例、腺鳞癌4例、支气管肺泡癌2例、大细胞癌3例,临床分期Ⅲ期30例、Ⅳ期18例。所有患者接受吉西他滨+奥沙利铂治疗,吉西他滨1000 mg/m2,第1天和第8天,奥沙利铂130 mg/m2,第1天。21天为1周期,共进行2个周期。结果:总有效率为45.8%,临床分期Ⅲ期有效率50.0%,Ⅳ期38.89%,组间无区别。治疗后的主要毒副反应为血液学毒性。白细胞减少、贫血及血小板减少,其Ⅲ度和Ⅳ度发生率分别为29.17%、18.75%和31.25%。生存质量有明显改善。结论:采用吉西他滨联合奥沙利铂治疗NSCLC患者有较好疗效,毒副作用可以耐受,是老年晚期NSCLC患者较为合适的一线治疗方案。更多还原

【Abstract】 Objective: To evaluate the effects of gemcitabine and oxaliplatin on non-small cell lung cancer of clinical stage Ⅲ~Ⅳ in elderly patients.Methods: Fourty-eight patients suffering from non-small cell lung cancer from Jan.2005 to Jan.2008 in our hospital were enrolled.Among them,23 patients suffered from squamous carcinoma,16 from adenocarcinoma,4 from adenosquamous carcinoma,2 from alveolar carcinoma and 3 from large cell carcinoma.By clinical classification,30 patients belonged to stage Ⅲ and 18 were stage Ⅳ.All patients received the combined treatment with gemcitabine and oxaliplatin.Gemcitabine with the dose of 1000mg/m2 was injected on d1 and d8.Oxaliplatin with the dose of 130mg/m2 was injected on d1.Two courses were performed.The treatment effects and side effects were evaluated according to the WHO standard.Results: The total effective rate was 45.8%.The effective rate of stage Ⅲ was 50.0%,and that of stage Ⅳ was 38.89%.The effective rate for squamous carcinoma,adenocarcinoma and other cancers failed to show significant difference.The main side effects were leucocytopenia,anemia and thrombocytopenia.The life quality of study group was apparently improved.Conclusion: The combined therapy of gemcitabine and oxaliplatin for elderly patients suffering from non-small cell lung cancer has good effect and the side reactions are tolerable.更多还原